In vivo analysis of castanospermine, a candidate antiretroviral agent.
Castanospermine (1,6,7,8-tetrahydroxyoctahydroindolizine), an inhibitor of glycoprotein processing, has been shown to inhibit the human immunodeficiency virus type 1 (HIV-1) with acceptable toxicity in cultured cells. In contrast to reverse transcriptase inhibitors, castanospermine targets host enzymes. We have analyzed castanospermine in murine systems, using cultured cells as well as live animals. Plaque formation by Rauscher murine leukemia virus (RLV) was inhibited with a median inhibitory concentration (IC50) of 2 micrograms/ml. RLV-exposed BALB/c mice treated with a 20 day course of castanospermine starting 4 h postinoculation showed a dose-dependent inhibition of splenomegaly. Oral castanospermine therapy given to chronically RLV-infected mice prolonged median survival from 36 to 94 days when compared to untreated controls (p = 0.007). Castanospermine was better tolerated orally than intraperitoneally at the same dose. Toxic effects included weight loss, lethargy, and dose-dependent thrombocytopenia. At the highest intraperitoneal dose, lymphoid depletion occurred in thymus, spleen, and lymph nodes. We conclude that castanospermine is an active antiviral agent in animals and that prolonged oral administration is tolerable; however, when compared to 3'-azido-3'-deoxythymidine in the same murine system, castanospermine was less active and more toxic.
Ruprecht
R M
RM
Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Mullaney
S
S
Andersen
J
J
Bronson
R
R
D000470:Alkaloids / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D005959:Glucosidases / Q000037:antagonists & inhibitors*; D007212:Indolizines; D007942:Leukemia, Experimental / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D011925:Rauscher Virus / Q000187:drug effects / Q000502:physiology; D014407:Tumor Cells, Cultured / Q000187:drug effects; D010948:Viral Plaque Assay; D001617:beta-Glucosidase / Q000037:antagonists & inhibitors*; D054836:Indolizidines
D000470:Alkaloids; D000998:Antiviral Agents; D005959:Glucosidases; D007212:Indolizines; D001617:beta-Glucosidase; C037806:castanospermine; D054836:Indolizidines